Glaukos (GKOS)
NYSE:GKOS
Want to see GKOS full AI Analyst Report?
GKOS Stock Chart & Stats
$124.79
$1.50(0.96%)
At close: 4:00 PM EST
$124.79
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $146.75
Previous CloseN/A
Volume137.72K
Average Volume (3M)692.11K
Market Cap
$7.84B
Enterprise Value$7.84B
Total Cash (Recent Filing)$276.69M
Total Debt (Recent Filing)$103.06M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.28
Shares Outstanding58,733,910
10 Day Avg. Volume640,360
30 Day Avg. Volume692,113
Financial Highlights & Ratios
PEG Ratio-1.87
Price to Book (P/B)9.84
Price to Sales (P/S)12.73
P/FCF Ratio-119.57
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue14.22
Enterprise Value/Gross Profit18.21
Enterprise Value/Ebitda-196.08
Forecast
1Y Price Target
$142.91Price Target Upside14.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$613.29M
Bulls Say, Bears Say
Bulls Say
Diversified Growth PipelineMultiple growth drivers including corneal products, iDose, and other ophthalmic initiatives reduce single-product execution risk and increase chances for upside to estimates.
Epioxa CommercializationInitial Epioxa rollout is progressing with system placements across a large portion of the U.S. and encouraging payer conversations, supporting adoption and potential corneal business growth.
Financial Strength And MarginsHigh gross margins combined with a substantial cash and investment position enable continued investment behind commercialization and pipeline expansion without immediate financing pressure.
Bears Say
Near-term Sales Volatility From Product TransitionTransition from the legacy corneal therapy to the new system and planned patient stockpiling ahead of the launch are likely to depress corneal health sales temporarily, creating short-term revenue swings.
Regulatory And Reimbursement UncertaintyPotential Medicare local coverage decisions and updated implant label requirements that narrow eligible patients or impose additional clinical steps could restrict procedural uptake and complicate reimbursement.
Valuation RiskStock trades at a notable premium to peers, which could lead to downside if sales growth or product adoption fails to meet elevated expectations.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $146.75 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $7.84B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Aug 05, 2026 which is in 87 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Apr 29, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.281 by $0.101.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.21.
How many shares outstanding does Glaukos have?
Glaukos has 58,733,910 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.281. Following the earnings report the stock price went up 22.837%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.91 (14.52% Upside)
$142.91 (14.52% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 702.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.25%
12-Months-Change
Fundamentals
Return on Equity
-26.46%
Trailing 12-Months
Asset Growth
-7.54%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution and meaningful growth: record Q1 revenue (+41% reported), raised guidance, robust U.S. glaucoma performance driven by iDose TR, encouraging early commercial and access milestones for Epioxa (including CMS J-code and >100M covered lives), improved gross margin, and a deep clinical pipeline with clear regulatory timelines. Near-term challenges include payer adoption frictions for Epioxa during the miscellaneous J-code period, expected quarter-to-quarter volatility in Corneal Health during the Photrexa-to-Epioxa transition (notably a Q2 dip), potential international competitive and currency headwinds, modestly higher operating expenses to fund launches, and residual policy/LCD risk for interventional glaucoma. Overall, the positive commercial momentum, material guidance raise, margin accretion, and pipeline progress materially outweigh the near-term operational and access headwinds.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$142.91
▲(14.52% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.87% Insiders
34.81% Mutual Funds
4.95% Other Institutional Investors
32.90% Public Companies and
Individual Investors